J90 Stock Chart & Stats
€0.33
>-€0.01(-2.36%)
At close: 4:00 PM EDT
€0.33
>-€0.01(-2.36%)
Day’s Range― - ―
52-Week Range€0.24 - €0.70
Previous CloseN/A
Volume0.00
Average Volume (3M)5.45K
Market Cap
€31.45M
Enterprise Value€49.36
Total Cash (Recent Filing)€1.51M
Total Debt (Recent Filing)€68.00K
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding77,746,750
10 Day Avg. Volume3,931
30 Day Avg. Volume5,450
Financial Highlights & Ratios
PEG Ratio-1.72
Price to Book (P/B)13.94
Price to Sales (P/S)0.00
P/FCF Ratio-8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Recent LeverageVery low recent leverage reduces solvency pressure and limits interest-related demands on cash flow. This gives NurExone a cleaner balance sheet while it advances its pipeline, although future funding needs remain important for sustaining development.
CNS Exosome PlatformA defined exosome platform focused on central nervous system applications provides a coherent foundation for developing multiple therapeutic programs. Concentrating expertise and research around one delivery approach may support efficient pipeline expansion over the medium term.
Multi-Program PipelineHaving a lead program alongside additional CNS concepts creates more than one avenue for potential asset development. A broader pipeline can preserve future partnering or licensing optionality if individual candidates encounter development setbacks.
Bears Say
Pre-Revenue BusinessNurExone has not yet established commercial revenue, so its financial progress depends on advancing candidates toward development and eventual commercialization. Until then, there is no recurring product-sales base to support operations or validate market demand.
Widening Net LossesThe materially larger loss in 2025 shows that operating costs remain substantial relative to the company’s current development stage. Persistent losses reduce internal funding capacity and increase dependence on successful clinical progress or external capital.
Persistent Cash BurnConsistently negative operating and free cash flow means NurExone is consuming cash rather than funding research internally. Continued burn implies recurring financing needs, which can constrain development flexibility and create dilution risk for existing shareholders.
NurExone Biologic News
J90 FAQ
What was NurExone Biologic’s price range in the past 12 months?
NurExone Biologic lowest stock price was €0.24 and its highest was €0.70 in the past 12 months.
What is NurExone Biologic’s market cap?
NurExone Biologic’s market cap is €31.45M.
When is NurExone Biologic’s upcoming earnings report date?
NurExone Biologic’s upcoming earnings report date is Nov 20, 2026 which is in 70 days.
How were NurExone Biologic’s earnings last quarter?
NurExone Biologic released its earnings results on Aug 31, 2026. The company reported €0.017 earnings per share for the quarter, beating the consensus estimate of -€0.017 by €0.034.
Is NurExone Biologic overvalued?
According to Wall Street analysts NurExone Biologic’s price is currently Overvalued.
Does NurExone Biologic pay dividends?
NurExone Biologic does not currently pay dividends.
What is NurExone Biologic’s EPS estimate?
NurExone Biologic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NurExone Biologic have?
NurExone Biologic has 77,746,750 shares outstanding.
What happened to NurExone Biologic’s price movement after its last earnings report?
NurExone Biologic reported an EPS of €0.017 in its last earnings report, beating expectations of -€0.017. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of NurExone Biologic?
Currently, no hedge funds are holding shares in DE:J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NurExone Biologic
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Technical Analysis
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Hemostemix
―
Sernova
―
Vaxil Bio
―